Skip to content

Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients

Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06468618
Acronym
DREAMS
Enrollment
10
Registered
2024-06-21
Start date
2024-08-06
Completion date
2027-08-01
Last updated
2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep Disturbance, Stem Cell Transplant Complications

Brief summary

Pediatric patients undergoing stem cell transplant (SCT) are hospitalized for extended periods and are at high risk for sleep disturbances. In order to begin to address the environmental issues that SCT recipients face during inpatient hospitalizations, investigators will conduct a single arm pilot study of a program entitled 'Developing Restful Environments and Management Strategies' (DREAMS). The program will provide children receiving SCT and families with information and a kit that includes tools which may support sleep and circadian health during an inpatient hospitalization.

Detailed description

In prior work, investigators conducted a study in which sound and light levels were recorded at one-minute intervals within an inpatient room on the SCT unit at Boston Children's Hospital using noise and light meters. Results showed that pediatric SCT recipients were consistently exposed to disruptive noise and light. Nighttime noise levels always exceeded World Health Organization recommendations for sleep, with recipients regularly exposed to multiple noise spikes associated with night wakings. While light levels were frequently dim enough to be conducive to sleep at night, participants were rarely exposed to light bright enough to preserve a healthy circadian rhythm during the day, which has the potential to dysregulate sleep at night. As a child's circadian rhythms may be affected by evening light to a greater extent than adults, such light spikes may be particularly disruptive to circadian rhythms in pediatric participants. The relatively low and afternoon-skewed daytime light, combined with the brighter than recommended light during the evening and early night, has been associated with longer hospitalizations and higher morbidity among adults. This is a single-arm pilot study to evaluate the acceptability and feasibility of the DREAMS intervention program in stem cell transplant pediatric participants to help support families during this critical phase in a participant's SCT recovery. The data collected from this study will help understand the practicality of delivering the program to a greater number of participants and conducting clinical research about the program in the setting in which it will be implemented. The research study procedures include screening for eligibility and surveys. Participation in this research study is expected to last for about 2 weeks. It is expected that about 10 children will take part in this research study. The American Cancer Society is supporting this research study with grant funding.

Interventions

BEHAVIORALDREAMS Program Video and Care Kit

A pediatric, circadian health program comprised of an introductory video to sleep experiences for stem cell transplant recipients, strategies to improve sleep, and a Sleep and Circadian Care Kit which includes ear plugs, a white noise machine, an eye mask, a lightbox, and kit instructions. Actigraph, Fitbit, and tablet will be provided to participant and family.

Sponsors

Dana-Farber Cancer Institute
Lead SponsorOTHER
American Cancer Society, Inc.
CollaboratorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
9 Years to 17 Years
Healthy volunteers
No

Inclusion criteria

* Patient aged 9-17 years. * Patient scheduled to receive a stem cell transplant at Boston Children's Hospital. * English speaking child and primary caregiver (parent/guardian).

Exclusion criteria

-Primary team declines permission to approach.

Design outcomes

Primary

MeasureTime frameDescription
Enrollment RateScreening (Day -30 to -1)Defined as the proportion of eligible participants approached by research staff and consent to participate in the study with the cutoff set at ≥30% of eligible participants that are approached and agree to participate.
Acceptability of Intervention Measure Scale ScoreAt Follow-up Assessment Visit (Day 21, up to Day 28)Participants reporting an average score of ≥4 ("Agree") on the Acceptability of Intervention Measure scale, a four-item questionnaire assessing the acceptability of an intervention, on a 5-point scale with options ranging from Completely Agree to Completely Disagree.
DREAMS Care Kit Usage RateAt Follow-up Assessment Visit (Day 21, up to Day 28)Feasibility of the DREAMS Program intervention is defined as ≥50% of participants reporting usage of at least one of the Care Kit materials.
Intervention Assessment Completion RateAt Follow-up Assessment Visit (Day 21, up to Day 28)Feasibility of the DREAMS Program intervention is defined as ≥80% of enrolled participants completing the Follow-up Assessment.

Secondary

MeasureTime frameDescription
Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance QuestionnaireBaseline and Follow-up Assessment Visit (Day 21, up to Day 28)An 8-item measure used to assess the extent of a child's poor sleep. The minimum score is 8, and the maximum score is 40. Higher scores indicate worse sleep disturbance outcomes.
Sleep DiaryDaily, for 1 week, during the study period.A self-report of a participant's daily sleep patterns, including bedtime and total sleep duration.
Program ExperienceAt Follow-up Assessment Visit (Day 21, up to Day 28)Open-ended questions regarding what was liked/disliked about the Care Kit materials.

Countries

United States

Contacts

CONTACTLucille Lokko, BA
lucille_lokko@dfci.harvard.edu617-632-6221
CONTACTEric Zhou, PhD
617-632-6162
PRINCIPAL_INVESTIGATOREric Zhou, PhD

Dana-Farber Cancer Institute

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 23, 2026